DPLD Flashcards

(55 cards)

1
Q

What are the main imaging patterns seen on HRCT?

A
  • Reticular (Linear)
  • Nodular
  • Ground-Glass
  • Consolidation
  • Cystic
  • Interlobular Thickening
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the causes of reticular patterns of disease on HRCT?

A

ACDCUIS (AC/DC Under the Influence of Something
* Asbestosis (similar to UIP, often with pleural plaques)
* Chronic HP
- Often associated with: ground-glass change, air trapping on expiration, centrilobular micronodules
* Drug-induced fibrosis
* Connective Tissue Disease (similar features to UIP)
* UIP
- Typically patchy, sub-pleural and basal
- Other features: loss of architecture of secondary pulmonary lobules, honeycombing, traction bronchiectasis
* Interstitial Pulmonary Oedema
* Sarcoidosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the causes of nodular patterns of disease on HRCT?

A
  • Interstitial Processes
  • Eg: Sarcoidosis
  • Airspace Disease
  • Due to acini becoming visible as nodules
  • HP, miliary TB, malignancy, COP (cryptogenic organising pneumonia)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are the causes of ground-glass change on HRCT?

A
  • Alveolar proteinosis
  • Bronchoalveolar cell carcinoma
  • Certain IIPs (NSIP, RB-ILD, DIP, AIP)
  • Drugs
  • Pulmonary oEdema/ARDS
  • Fungal (PCP) Infection
  • Great Imitator (Sarcoidosis)
  • Hypersensitivity Pneumonitis

Changes may also be artefactual:-
* Increased density (breath holding during expiration)
* Mosaic perfusion (chronic thromboembolic disease, gas trapping)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the features and causes of consolidation/airspace shadowing on HRCT?

A
  • Features
  • Air bronchograms (air-filled bronchi superimposed against opacified alveoli)
  • Loss of visibility of adjacent vessels
  • Due to filling of alveolar airspaces by infiltrative processes with water/blood/pus/malignant cells/fibrous tissue
  • Causes (HOPCODR)
  • Alveolar Haemorrhage
  • Pulmonary oedema/ARDS
  • Pneumonia
  • Cancer (bronchoalveolar cell carcinoma, lymphoma)
  • Organising Pneumonia
  • Drugs
  • Rare diseases (eosinophilic pneumonia, alveolar proteinosis)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are the causes of cystic change on HRCT?

A
  • Causes: EE, LLL, PU
  • Septic Emboli
  • Centrilobular Emphysema
  • LAM (lymphangioleiomyomatosis) – thin-walled cysts, otherwise normal lungs)
  • LIP (lymphoid interstitial pneumonia)
  • LCH (Langerhans Cell Histiocytosis) – bizarrely shaped cysts and nodules with apical predominance)
  • PCP
  • UIP
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is the process for and the causes of interlobular septal thickening on HRCT?

A
  • Process:-
  • Due to process affecting interlobular septal lymphatics or venules
  • Causes
  • Pulmonary oedema (smooth thickening)
  • Lymphangitis carcinomatosis (irregular, nodular thickening, no architectural distortion)
  • Sarcoidosis
  • UIP
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are the typical causes of particular distributions of disease seen on HRCT?

A
  • Upper zone
  • Silicosis
  • Pneumoconiosis
  • Chronic sarcoidosis
  • Hypersensitivity pneumonitis
  • Ankylosing spondylitis
  • TB
  • LCH
  • Lower Zone
  • UIP
  • CTD
  • Asbestosis
  • Mid-Zone
  • Sarcoidosis
  • Pulmonary oedema
  • PCP
  • Peripheral
  • UIP
  • Eosinophilic pneumonia
  • Drugs (amiodarone)
  • Copt (cryptogenic organising pneumonia)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are the different HRCT features, histological features, onsets and prognosis of the different IIPs?

A

IIP Onset HRCT Features Histology Prognosis

IPF (prev CFA) Months-years Fibrosis, honeycombing, subpleural/basal distribution, minimal GGO Interstitial fibrosis (foci of proliferating fibroblasts), interspread with normal lung, minimal inflammation Poor

NSIP Months-years GGOs, fine reticulation, basal distribution, minimal honeycombing Varying degrees of inflammation and fibrosis, more uniform than UIP Variable, can be good

COP (cryptogenic organising pneumonia) Months Consolidation, basal, subpleural, peribronchial predominance Plugged alveolar spaces, granulation tissue +/- extension into bronchioles Poor

AIP (Acute Interstitial Pneumonia) Days Diffuse GGO, patchy consolidation Diffuse alveolar damage, interstitial oedema. Follower by fibroblast proliferation and fibrosis Poor

RB-ILD (Respiratory Bronchiolitis) Years (with mild symptoms) Centrilobular nodules, GGOs, thick-walled airways Pigmented macrophages in bronchioles Good

DIP (Desquamative Interstitial Pneumonia) Weeks-months GGOs Pigmented macrophages in alveolars spaces Good

LIP (Lymphoid Interstitial Pneumonia) Years GGOs, reticulations, cysts Diffuse interstitial lymphoid infiltrates Variable

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are the HRCT features of IPF?

A
  • Reticulations – bilateral, basal and subpleural
  • Honeycombing
  • Traction bronchiectasis
  • Minimal/no GGOs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are the features of BAL in IPF?

A
  • Not routinely required, rarely helpful
  • Features:
  • Neutrophilia
  • Mild eosinophilia (sometimes)
  • Marked eosinophilia (>20%) or lymphocytosis (>50%) suggest alternative diagnosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are the histological features of IPF?

A
  • Heterogenicity
  • Patches of active fibroblastic foci (acute injury)
  • Honeycombing/architectural distortion (chronic scarring)
  • Areas of normal lung
  • Interstitial inflammation is minimal
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the prognosis of IPF, and what are poor prognostic factors?

A
  • Variable, mean 3-5 years
  • Poor prognostic factors:-
  • TLCO <40% at presentation
  • 6MWT desat <88%
  • Decline in FVC ≥10% or TLCO ≥15% in first 6-12/12
  • PHT (particularly poor prognosis)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are the management options for IPF?

A

Supportive measures
* Pulmonary Rehab – can be repeated annually
* Hypoxia - Oxygen (if pO2 <7.3 or <8 with features of PHTN)
* GORD - PPI +/- motility agents (eg domperidone)
- GORD is common in IPF and may drive fibrosis
* Cough – opiates (codeine, IR morphine, possibly thalidomide)

Antifibrotics
* Pirfenidone
* Nintedanib
* Acetylcysteine

Lung Transplantation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are the mechanisms, indications, monitoring requirements, side effects and definitions of treatment failure in the antifibrotics for IPF?

A
  • Pirfenidone
  • Mechanism: inhibits collagen synthesis, reduces fibroblast proliferation
  • Indication: FVC 50-80%
  • Monitoring: monthly FBC/LFT for 6/12, then 3-monthly
  • S/E: LFT derangement, GI symptoms
  • Treatment failure: FVC decline of ≥10% within 1 year
  • Nintedanib
  • Mechanism: TK inhibitor – inhibits PDGFR, FGFR and VEGFR ( platelet-derived, fibroblast and vascular endothelial growth factor receptors)
  • Indication: FVC 50-80%
  • Monitoring: monthly FBC/LFT for 6/12, then 3-monthly
  • S/E: bleeding (not recommended for patients on anticoagulation), LFT derangement, GI symptoms
  • Treatment failure: FVC decline of ≥10% within 1 year
  • Acetylcysteine
  • Mechanism: antifibrotic and antioxidant
  • Widely used, no harm, no evidence of benefit
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are the guidelines (and also realistic requirements) for patients with IPF to be referred for lung transplantation?

A
  • Guidance – all suitable patients should be referred (irrespective of VC)
  • Reality – symptomatic, age <65, TLCO <40%, FVC decline ≥10% in 6/12, TLCO decline ≥15% in 6/12, 6MWT desat <88%, acute/rapid deterioration
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What are the radiological classifications of NSIP?

A
  • NSIP with IPF-like profile/overlap (NSIP/IPF)
  • NSIP with OP profile (NSIP/OP)
  • NSIP with HSP profile (NSIP/HSP)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What are the X features of ?

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What are the associations and causes of NSIP?

A
  • Idiopathic
  • CTD (NSIP can be the first manifestation)
  • Drugs
  • Infection
  • Immunodeficiency (HIV, post-BM transplant, chemotherapy)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What are the clinical features of NSIP?

A
  • Breathlessness/cough
  • Weight loss (common)
  • Gradual/subacute onset (0.5-3 years from symptoms to diagnosis)
  • Basal crackles, later more extensive
  • Clubbing (small proportion)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What are the investigations and typical findings of NSIP?

A
  • HRCT
  • GGOs, often basal distribution
  • Typically more confluent/homogenous pattern than IPF
  • Reticulations and traction bronchiectasis may or may not occur
  • Honeycombing usually absent (except fibrotic NSIP)
  • Physiological Testing
  • Spirometry – restrictive
  • DLCO – impaired in only 50%
  • SpO2 – desaturation on exertion is common
  • BAL – lymphocytosis
  • Lung Biopsy – often required, with variable histology:-
  • NSIP 1 (primarily cellular/inflammation) – interstitial inflammation, no fibrosis
  • NSIP 2 (inflammation and fibrosis)
  • NSIP 3 (primarily fibrosis) – fibrosis, more homogenous than UIP, lacks fibroblastic foci or honeycombing
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What are the diagnostic requirements for NSIP

A
  • Lung biopsy often required
  • If presence of CTD -> biopsy often not required
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What are the management of NSIP?

A
  • Monitoring - serial PFTs (FVC + TLCO)
  • Decrease of 10-15% considered significant
  • Treatment
  • Prednisolone – 0.5mg/kg
  • Bone protection
  • Consideration of PPI
  • Consideration of PCP prophylaxis (co-trimoxazole 960m mg x3/week)
  • Immunosupression if fails to respond to steroids (eg. Azathioprine, MMF)
24
Q

Define COP

A
  • Cryptogenic = unknown cause, although OP can occur in association with other disease
  • Characteristics – ‘plugging’ of alveolar spaces with granulation tissue, sometimes extending into bronchioles
25
What are the cause of OP?
* Cryptogenic * Organising pneumonia secondary to (ABCIII):- - Airway obstruction - (Post) Bone marrow transplant - CTD (myositis, RA, Sjorgen’s), Cancer (lung and haematological malignancy, radiotherapy) - Drugs, DAD (diffuse alveolar damage) - Infection (lung abscess, pneumonia, bronchiectasis), IBD, pulmonary infarction)
26
What are the clinical features of OP?
* Short history (<3 months) * Dyspnoea (often mild) + dry cough - Some develop severe dyspnoea with rapid onset respiratory failure -> “fulminant COP” * Often systemic features – malaise, fever, weight loss, myalgia
27
What are the investigations and findings of OP?
* Bloods – neutrophilia, raised CRP, raised ESR * Lung function – mild-mod restrictive pattern * CXR – patchy consolidation, sometimes nodular shadowing * HRCT - Consolidation with air bronchograms - Sometimes associated with GGOs or small nodules - Location – often basal, subpleural and peribronchial - Reticulation – suggests poor response to treatment - Solitary mass (rare) – can lead to cavity * TBB – can be diagnostic for patients with typical features * BAL – lymphocytosis, neutrophila and eosinophilia
28
What are the histological features of OP?
* Alveolar spaces ‘plugged’ with granulation tissue (fibrin, collagen-containing fibroblasts, inflammatory cells) – can extend up to bronchiolar lumen * Patchy * Lack of architectural distortion * Evidence of underlying cause – infection, vasculitis
29
What are the diagnostic requirements of OP?
* Made on the basis of clinical, HRCT and biopsy findings * Histological findings often non-specific – should search for cause of OP
30
What is the management of OP?
* Normal management: prednisolone - 0.5-1.5mg/kg for 1-3 months - Taper over 6-12 months * Fulminant disease: methylprednisolone then prednisolone - pulsed IV methylpred, 0.75-1mg x3 - then prednisolone maintenance 0.5-1mg/kg * If poor response to steroids - Azathioprine or - Cyclophosphamide (can be pulsed pulsed in critically ill patients after 5-7 days with no steroid response
31
What are the clinical features of AIP?
* Often preceded by ‘viral’-type illness * Systemic symptoms: fevers, fatigue, myalgia, arthralgia * Rapid onset (days) of dyspnoea
32
What are the investigations and findings of AIP?
* CXR: - Diffuse airspace shadowing with air bronchograms - Bilateral and diffuse - Often spares CP-angles/heart borders/hila * HRCT - Early: bilateral/diffuse/patchy GGOs and airspace shadowing - Late: reticulations, traction bronchiectasis, cystic change * PFTs - Restrictive spirometry - Reduced DLCO - Also profound hypoxia and respiratory failure * BAL - Increased total cells, red blood cells and haemosiderin - Non-diagnostic, helps to exclude infection * Lung biopsy - Required for diagnosis
33
What are the histological findings of AIP?
* Diffuse alveolar damage * Hyaline membranes * Oedema * Interstitial inflammation * Alveolar septal thickening * Advanced disease: organising fibrosis and honeycombing
34
What is the management of AIP?
* Supportive * High dose steroids (pulsed methylpred then pred) may be of help – although more likely fulminant COP rather than AIP.
35
What are the differences between RB, RB-ILD and DIP?
* RB - Accumulation of bronchiolar pigmented macrophages in cigarette smokers - Nearly always asymptomatic * RB-ILD - An ILD that develops in a minority of cases * DIP - Felt to be a more extensive accumulation of pigmented macrophages causing more advanced ILD - Macrophages located more diffusely throughout alveolar airspaces
36
What are the clinical features of RB-ILD?
* Mild dyspnoea and cough - Small proportion have severe dyspnoea and respiratory failure * Crackles
37
What are the investigations and findings for RB-ILD?
* PFTS - Restrictive or combined restrictive and obstructive disease - Mildly impaired DLCO * CXR - Thick walled bronchi - Reticular change - GGOs - May be normal * HRCT - Centrilobular nodules - GGOs - Thick-walled airways - Often centrilobular emphysema present * BAL - Pigmented alveolar macrophages
38
What are the histological findings of RB-ILD?
* Pigmented brown macrophages in terminal bronchioles * Patchy bronchiolocentric distribution * Findings frequently found in healthy smokers
39
What is the management of RB-ILD?
* Smoking cessation * Steroids occasionally used
40
What are the clinical features of DIP?
* Cough and dyspnoea – onset over weeks-months * Clubbing present (50%)
41
What are the investigations and findings in DIP?
* PFTs - Mild restrictive pattern - Sometimes reduced DLCO * CXR - Normal often - Reticulations - GGOs - Particularly affects lower zones * HRCT - GGOs - Reticulations and honeycombing can be present (often mild) - Lower or peripheral zones dominant * BAL – pigmented macrophages
42
What are the diagnostic requirements for DIP?
* Lung biopsy often required * Histology – diffuse accumulation of pigmented macrophages in alveolar airspaces, changes are uniform
43
What is the management of DIP?
* Smoking cessation * Steroids often used – responds well
44
What is LIP?
Lymphoid Interstitial Pneumonia (LIP) * Diffuse lymphoid infiltrates and lymphoid hyperplasia causing interstitial pneumonia * Minority of cases idiopathic, most have an association/cause
45
What are the causes and associations of LIP?
* Autoimmune Disease - Haemolytic anaemia - Hashimoto’s thyroiditis - Pernicious anaemia - Chronic active hepatitis - PBC - MG * Connective Tissue Disease - Sjorgen’s syndrome - Rheumatoid arthritis - SLE * Drugs - Phenytoin * Infection - PCP - HBV * Immunodeficiencies - HIV - Common variable immunodeficiency * Idiopathic
46
What are the clinical features of LIP?
* Gradual-onset dyspnoea and cough (years) * Systemic features – fever, weight loss * Crackles
47
What are the investigations and findings in LIP?
* Bloods - Mild anaemia may occur - Poly- or monoclonal increase in serum immunoglobulins * CXR - Alveolar shadowing (lower zone) - Diffuse honeycombing * HRCT - GGOs - Reticulations - Cysts (differentiates from NSIP) - Honeycombing and nodules (occasionally) * BAL – non-clonal lymphocytosis
48
What are the histological findings in LIP?
* Diffuse interstitial lymphoid infiltrates * Predominantly involving alveolar septa * Occasional lymphoid hyperplasia or honeycombing * Similar appearance to: cellular NSIP, follicular bronchiolitis and lymphoma
49
What is the management of LIP?
Steroids
50
What are some of the causes of HP?
Disease Source Antigen Farmer’s Lung Mouldy hay Aspergillus species Thermophillic actinomycetes (thermoactinomyces vulgaris, micropolyspora faeni) Bagossosis Mouldy bagasse (pressed sugarcane) As above Compost lung Compost As above Mushroom workers Lung Mushrooms As above Humidifier lung Contaminated water in humidifiers and A/C units As above Malt Worker’s Lung Mouldy barley Aspergillus clavatus Summer-house HP (Japan) House dust Trichosporon cutaneum Hot Tub Lung Hot tub mist, ceiling mould M. Avium Complex Bird Fancier’s Lung Bloom and bed feathers and droppings Bird/avian proteins Rat Lung Rat droppings Rat proteins Isocyanate HP Paints Toluene dissocyanate
51
What is the pathophysiology of HP?
* Not fully understood * Likely Type IV hypersensitivity reaction (T-Cell mediated and granuloma formation) * And/or Type IV hypersensitivity reaction (antibody-antigen immune complex formation) * Not an atopic disease – not Type I hypersensitivity (rise in tissue eosinophils or IgE)
52
What are the clinical findings (symptoms and examination) of acute HP and chronic HP?
Acute HP * Symptoms (4-8hrs after antigen exposure) - Dry cough - Dyspnoea - Systemic symptoms: fevers, chills, arthralgia, myalgia, headache - Settle within 1-3 days spontaneously (if exposure stopped) * Examination - Crackles - Squeeks - Wheeze Chronic HP * Symptoms (months-years) - Exertional dyspnoea - Dry cough - Sometimes systemic symptoms (weight loss) - May have history of acute episodes * Examination - Crackles - Squeeks - Features of cor pulmonale may be present
53
What are the investigations and findings in acute HP?
CXR * Nodules (small (1-3mm) and diffuse) * Infiltrates * GGOs * Apical sparing * Often normal (20%) HRCT * GGOs (patchy or diffuse) * Poorly-defined micronodules * Mosaic attenuation (enhanced on expiratory HRCT) - Occur due to air trapping from bronchiolar involvement) PFTs * Restrictive pattern * Reduced gas transfer * Reduced lung volumes * Mild obstruction can occur * May be normal Bloods * Neutrophilia * Raised inflammatory markers * Serum antibody (IgG) Precipiten - Found in 90% of patients, but also in significant numbers of asymptomatic patients with antigen exposure - Levels often fall in absence of ongoing antigen exposure BAL * Lymphocytosis (often >50%) = characteristic finding * Not diagnostic, also may be found in asymptomatic exposed individuals Transbronchial or surgical lung biopsy * May be required if diagnosis unclear * Histo - bronchiolocentric granulomatous lymphocytic pneumonitis
54
What are the investigations and findings in chronic HP?
CXR * Reticulations (upper and mid zone) * Reduced lung volumes HRCT * Diffuse centrilobular nodules * GGOs * Mosaic attenuation * Honeycombing * Traction bronchiectasis * Upper lobe predominance typical (differs from UIP) PFTs * Restrictive pattern * Reduced gas transfer * Reduced lung volumes * Mild obstruction can occur * May be normal Bloods * Raised inflammatory markers * Serum antibody (IgG) Precipiten - Found in 90% of patients, but also in significant numbers of asymptomatic patients with antigen exposure - Levels often fall in absence of ongoing antigen exposure BAL * Lymphocytosis (often >50%) = characteristic finding * Not diagnostic, also may be found in asymptomatic exposed individuals Transbronchial or surgical lung biopsy * May be required if diagnosis unclear * Histo - bronchiolocentric granulomatous lymphocytic pneumonitis
55
How is HP diagnosed?
* Typical presentation is diagnostic - History of antigen exposure - Typical clinical features - Typical HRCT features * Atypical presentation requires further investigations - BAL lymphocytosis - Histology (bronchiolocentric granulomatous lymphocytic pneumonitis)